GPIIIa gene

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9079961
APP PUB NO 20100173292A1
SERIAL NO

12451655

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

An object of the present invention is to provide a probe, primer, primer set and antibody for determining neonatal alloimmune thrombocytopenic purpura or the risk of developing it. According to the present invention, there is provided a probe, primer, primer set and antibody for use in the detection of the thymine residue at position 1297 in the GPIIIa.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
WAKUNAGA PHARMACEUTICAL CO LTD5-36 MIYAHARA 4-CHOME YODOGAWA-KU OSAKA-SHI OSAKA 532-0003
JAPANESE RED CROSS SOCIETYTOKYO 105-8521

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Ishii, Hiroyuki Osaka, JP 506 6576
Maekawajiri, Shinji Aki-Takata, JP 2 5
Nagata, Nozomi Aki-Takata, JP 1 1
Oka, Takanori Aki-Takata, JP 20 165
Taniue, Atsuko Osaka, JP 1 1

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 14, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00